Tagged with IP

Hong Kong Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.   “Biotechnology is today the fastest-growing IPO market segment,” says Nicolas Aguzin, CEO of HKEX, one of the world’s major…

France The latest news from French pharma, including AI-based biotech Owkin’s new status as a USD one billion-valued unicorn following fresh investment from Sanofi. Also included is another deal for Sanofi, this time in the form of a partnership with Chinese tech giant Baidu to use its algorithm for mRNA sequencing.…

Saudi Arabia Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing…

Turkey Few Turkish companies are experiencing such a transformational moment as GEN. Just in 2021, the Ankara-based organization made its public debut at the Istanbul Stock Exchange and signed an exclusive collaboration agreement with a Dutch biotech company for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative…

China The latest reporting on China biopharma dealmaking from MSQ Ventures, including the Top 10 biotech in-licensing deals in H1 2021, the Top 5 out-licensing deals, and Top 10 IPOs.   Made with Visme Infographic Maker Made with Visme Infographic Maker Made with Visme Infographic Maker

Global Pharma industry leaders have called for rich nations to stop stockpiling excess COVID-19 vaccine doses and stated that there will be enough production by the end of the year to cover the entire global population. The head of Pfizer, J&J, and industry association the IFPMA also hope that this surge…

Spain The Spanish pharma industry has entered the race to develop COVID-19 vaccines through an unexpected contender: an animal health company. HIPRA, headquartered in Catalonia, has received approval to begin human trials and expects to manufacture over 400 million doses in 2022.   While Spain ranks amongst the top 10 countries…

China In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the country’s domestic biopharma innovation landscape and the ability of breakthrough drugs from MNCs to make it onto the Chinese market. …

Morocco After implementing the most successful COVID-19 inoculation campaign on the African continent, Morocco is looking to bolster its biologics and vaccine manufacturing capacity via two major agreements with Swedish CDMO Recipharm and Chinese Sinopharm. The North African nation hopes to be better able to supply the health needs of its…

Turkey After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to her country by improving patients’ access to life-saving therapies.   For Russ, what began as a consultant role at McKinsey…

Brazil The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine in Brazil; and how domestic champion EMS surged in performance in 2020 thanks to COVID.   Brazil probes Health Ministry…

Hong Kong With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and what the recent appointment of a new CEO – the first foreign appointment in its history – means for the…